Safety, efficacy, and immunogenicity of elosulfase alfa in patients with Morquio syndrome type A participating in 2 sequential open-label studies (MOR-002/MOR-100), representing 5 years of treatment

Hendriksz Christian; Santra Saikat; Jones Simon A.; Geberhiwotd Tarekegn; Jesaitis Lynne; Long Brian; Qi Yulan; Hawley Sara M.; Decker Celeste

首页> 外文期刊>Molecular genetics and metabolism >Safety, efficacy, and immunogenicity of elosulfase alfa in patients with Morquio syndrome type A participating in 2 sequential open-label studies (MOR-002/MOR-100), representing 5 years of treatment

【24h】

Safety, efficacy, and immunogenicity of elosulfase alfa in patients with Morquio syndrome type A participating in 2 sequential open-label studies (MOR-002/MOR-100), representing 5 years of treatment

机译：紫苏蛋白Alfa在Morquio综合征患者中的安全性，疗效和免疫原性，参与2个顺序开放标签研究（Mor-002 / Mor-100），代表5年的治疗方法

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Molecular genetics and metabolism 》 |2018年第2期| 共1页
作者
Hendriksz Christian; Santra Saikat; Jones Simon A.; Geberhiwotd Tarekegn; Jesaitis Lynne; Long Brian; Qi Yulan; Hawley Sara M.; Decker Celeste;
展开▼
作者单位

Univ Pretoria Pretoria South Africa;

Birmingham Childrens Hosp NHS Fdn Trust Birmingham W Midlands England;

Univ Manchester Manchester Lancs England;

New Queen Elizabeth Hosp Birmingham W Midlands England;

BioMarin Pharmaceut Inc Novato CA USA;

BioMarin Pharmaceut Inc Novato CA USA;

BioMarin Pharmaceut Inc Novato CA USA;

BioMarin Pharmaceut Inc Novato CA USA;

BioMarin Pharmaceut Inc Novato CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病 ;
关键词

相似文献

外文文献
中文文献

1. Safety, efficacy, and immunogenicity of elosulfase alfa in patients with Morquio syndrome type A participating in 2 sequential open-label studies (MOR-002/MOR-100), representing 5 years of treatment [J] . Hendriksz Christian, Santra Saikat, Jones Simon A., Molecular genetics and metabolism . 2018 ,第2期

机译：紫苏蛋白Alfa在Morquio综合征患者中的安全性，疗效和免疫原性，参与2个顺序开放标签研究（Mor-002 / Mor-100），代表5年的治疗方法
2. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002/MOR-100), representing 5 years of treatment [J] . Hendriksz Christian, Santra Saikat, Jones Simon A., Molecular genetics and metabolism . 2018 ,第4期

机译：Morquio A综合征患者的安全性，免疫原性和临床结果参与了Elosulfase Alfa酶替代疗法（Mor-002 / Mor-100）的2个顺序开放标签研究，代表了5年的治疗方法
3. Long-term treatment with elosulfase alfa has an acceptable safety profile for patients with Morquio syndrome type A: Real-world results from the Morquio A Registry Study (MARS) [J] . Molecular genetics and metabolism . 2020 ,第2期

机译：用elosulfase Alfa的长期治疗对于Morquio综合征类型A患者具有可接受的安全性曲线：Morquio的实际结果是登记册研究（火星）
4. Study of Efficacy and Safety of Willow Bark Extract (Assalix) in Treatment of Chronic Low Back Pain in Patients of Different Age with Osteochondrosis [C] . V.V. Povoroznyuk, T.A. Karasevskaya International Pain Clinic Congress . 2008

机译：柳树皮提取物（Assalix）治疗不同年龄患者慢性低腰疼痛的疗效和安全性研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study [O] . Christian J. Hendriksz, Barbara Burton, Thomas R. Fleming, -1

机译：BMN 110（依法硫酸法）酶替代疗法对Morquio A综合征（黏多糖贮积症IVA）的疗效和安全性：3期随机安慰剂对照研究
7. Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study [O] . Paul R. Harmatz, Eugen Mengel, Tarekegn Geberhiwot, 2016

机译：elosulfase Alfa对Morquio A综合征患者的影响：开放标签，第2期研究

Safety, efficacy, and immunogenicity of elosulfase alfa in patients with Morquio syndrome type A participating in 2 sequential open-label studies (MOR-002/MOR-100), representing 5 years of treatment

著录项

相似文献

相关主题

期刊订阅